Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm phase 4 study of carfilzomib + lenalidomide + dexamethasone in newly diagnosed multiple myeloma
ChiCTR2400079665Phase 4Recruiting
- Sponsor
- Qingdao Municipal Hospital
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Qingdao Municipal Hospital. Primary endpoint: Rate of at least very good partial response after induction therapy. Started Jan 2024; status: recruiting.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400079665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079665.